23andMe CEO Anne Wojcicki is considering splitting the company’s consumer and therapeutics businesses in an effort to revive the stock price and avoid being delisted, Kristen Brown of Bloomberg reports “We’re exploring different opportunities,” Wojcicki said in an interview with Bloomberg. “When we decided to do drug discovery, it was a commitment to saying we are going to be burning cash,” said Wojcicki.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ME:
- 23andMe FDA Approval for Novel Cancer Drug Trial
- 23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
- 23andMe announces FDA clearance of IND application for 23ME-01473
- 23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
- 23andMe to Report FY2024 Third Quarter Financial Results
